Two retrospective studies with 15 [56] and 19 [57] patients treated with platinum and Pemetrexed combinations before TKI in 2011 reported an mPFS of 9.2 and 9 months, respectively, much longer than in patients with EGFR or wild-type lung cancer, thus suggesting that ALK-positive tumours could be highly sensitive to Pemetrexed chemotherapy. This evidence concerns the gene ALK and lung cancer.